Abstract
The authors wish to make the following corrections to their article: Anderson SL. New and emerging treatments for PBC-related pruritus. Drugs Context. 2026;15:2025-12-3. https://doi.org/10.7573/dic.2025-12-3
Corrigendum
The authors regret that there are errors in their original paper.
The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).
Page 7
Neither linerixibat nor volixibat is currently approved by the FDA or EMA for PBC-related pruritus. Volixibat has not yet been approved by the FDA or EMA for PBC-related pruritus.